Portal de recerca
- Inici
- Projectes i Estudis Clínics
- ENSAYO CLÍNICO ABIERTO Y MULTICÉNTRICO DE NIVOLUMAB (BMS-936558) EN MONOTERAPIA EN SUJETOS CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) EPIDERMOIDE AVANZADO O METASTÁSICO QUE HAN RECIBIDO AL MENOS DOS LÍNEAS DE TRATAMIENTO SISTÉMICO PREVIAS PARA EL TRATAMIE NTO DEL CPNM EPIDERMOIDE EN ESTADIO IIIB/IV.
ENSAYO CLÍNICO ABIERTO Y MULTICÉNTRICO DE NIVOLUMAB (BMS-936558) EN MONOTERAPIA EN SUJETOS CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) EPIDERMOIDE AVANZADO O METASTÁSICO QUE HAN RECIBIDO AL MENOS DOS LÍNEAS DE TRATAMIENTO SISTÉMICO PREVIAS PARA EL TRATAMIE NTO DEL CPNM EPIDERMOIDE EN ESTADIO IIIB/IV.
Dades bàsiques
- Protocol:
- CA209-171
- EURDRACT:
- 2014-001285-10
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2015
- Any de finalització:
- 2021
Objectius del projecte
Observaciones: Estado Comité: ACTIVO
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
Provencio-Pulla, Mariano; (...); Rueda, Antonio
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7550. 2018
A consensus statement on the gender perspective in lung cancer
Isla, D; (...); de Castro, J
Review. 10.1007/s12094-016-1578-x. 2017
A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 2021
A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 2017
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
Juan, O, Popat, S
Review. 10.1016/j.cllc.2017.03.002. 2017
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
Morgensztern, D; (...); ABOUND 2L Investigators
Article. 10.1002/cncr.31779. 2018
Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution
Bruixola, G; (...); Aparicio, J
Article. 10.5301/tj.5000344. 2015
ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION-POSITIVE TUMOURS
Isla D; (...); Rubio-Rodríguez D
Meeting Abstract. 10.1016/j.jval.2015.09.1017. 2015
Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Romero, A; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2019.08.1463. 2019
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma
Fernandez-Mateos, J; (...); Gonzalez-Sarmiento, R
Article. 10.1038/s41598-017-07270-0. 2017
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A; (...); Oramas J
Article. 10.21037/tlcr-21-559. 2021
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Conde, E; (...); Lopez-Rios, F
Article. 10.1016/j.jtho.2019.07.005. 2019
Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer
Garrido, P; (...); Vinolas, N
Meeting Abstract. 10.1016/j.jtho.2019.08.685. 2019
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study
Gonzalez-Cao, M; (...); Rosell, R
Article. 10.1001/jamaoncol.2020.0465. 2020
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D; (...); Provencio M
Article. 10.1016/j.patol.2019.11.002. 2020
ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
Baz, DV; (...); Pulla, MP
Meeting Abstract. 10.1016/S1556-0864(18)30430-1. 2018
ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Nadal, E; (...); Bruna, J
Meeting Abstract. 10.1016/j.jtho.2019.08.826. 2019
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Bulky mass tumor in right foot
Coloma, CS; (...); Gomez, OMN
Editorial Material. 10.1093/jjco/hyv075. 2015
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Jimenez-Cortegana, C; (...); de la Cruz-Merino, L
Article. 10.1136/jitc-2020-002323. 2021
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, T; (...); Torres, JMS
Article. 10.1016/j.cllc.2020.04.011. 2020
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; (...); Cordoba, Raul
Article. 10.1111/bjh.16741. 2021
Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)
Franco, FF; (...); Provencio, M
Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021
Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia, Jon; (...); Paz-Ares, Luis G.
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.9101. 2018
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Zugazagoitia, J; (...); Garrido, P
Article. 10.1016/j.lungcan.2019.05.032. 2019
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J; (...); Paz-Ares, L
Article. 10.1093/annonc/mdy512. 2019
Clinical Utility of Plasma-Based NGS for AdvancedStage NSCLC Patients with Insufficient or Unavailable Tumor Tissue
Zugazagoitia, J.; (...); Garrido, P.
Meeting Abstract. 2017
Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.
Romero, Atocha; (...); Provencio-Pulla, Mariano
Meeting Abstract. 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.
Romero A; (...); Provencio M
Article. 10.1002/1878-0261.12832. 2020
Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for secondline treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.
Rojo, Federico; (...); De Castro, Javier
Meeting Abstract. 2020
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
Provencio, M; (...); Rueda, A
Letter. 10.1080/10428194.2018.1509322. 2019
Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.
Pardo-Sanchez, Jose Miguel; (...); Farràs R
Article. 10.3390/cancers13194825. 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck, M.; (...); John, T.
Correction. 10.1016/j.esmoop.2021.100345. 2021
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.
Isla, D; (...); Rubio-Rodriguez, D
Article. 10.2147/CEOR.S121093. 2017
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
Juan, O, Popat, S
Editorial Material. 10.1016/j.lungcan.2016.11.007. 2017
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Becker JH; (...); Shimamura T
Article. 10.1158/0008-5472.CAN-19-0024. 2019
Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Becker, J; (...); Shimamura, T
Meeting Abstract. 10.1016/j.jtho.2019.08.1478. 2019
Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)
Franco, F; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020
Development of severity and mortality prediction models for covid-19 patients at emergency department including the chest x-ray.
Calvillo-Batllés P; (...); Martí-Bonmatí L
Article. 10.1016/j.rxeng.2021.09.004. 2022
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke
Puig, J; (...); Pedraza, S
Review. 10.1007/s00234-017-1816-0. 2017
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
Ferris, RL; (...); Licitra, L
Article. 10.1016/j.annonc.2020.04.001. 2020
Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients
Salvador-Coloma, C; (...); Santaballa, A
Meeting Abstract. 2018
Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations
Salvador Coloma, C.; (...); Juan, O.
Meeting Abstract. 10.1016/S1556-0864(16)30269-6. 2016
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY
de Castro, J; (...); Rojo, F
Meeting Abstract. 2020
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
Angelats, L; (...); Costa, EC
Meeting Abstract. 2019
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Reck, M; (...); Spigel, DR
Meeting Abstract. 2018
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Morgensztern, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.626. 2018
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Remon, J; (...); Felip, E
Article. 10.1007/s12094-017-1700-8. 2017
Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin Et Chemo-Radiation in Stage III NSCLC. SLCG 10/02
Isla, D; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2016.11.421. 2017
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma
Pulido, I; (...); Shimamura, T
Article. 10.1158/0008-5472.CAN-20-0141. 2020
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location
Seijas-Tamayo, R; (...); Cruz-Hernandez, JJ
Article. 10.1007/s12094-016-1493-1. 2016
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Franco, F; (...); Provencio, M
Article. 10.1371/journal.pone.0251761. 2021
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell, R; (...); BELIEF collaborative group
Article. 10.1016/S2213-2600(17)30129-7. 2017
Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Conde, E; (...); Lopez-Rios, F
Meeting Abstract. 10.1016/j.jtho.2018.08.785. 2018
Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Cao, MG; (...); Costa, RR
Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020
Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Calvo, V; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020
Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
Calvo, V.; (...); Provencio, M.
Meeting Abstract. 2021
Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
Edelman, MJ; (...); Saunders, A
Meeting Abstract. 10.1016/S1556-0864(18)30363-0. 2018
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Pulla, MP; (...); Casado, MDI
Meeting Abstract. 2018
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemoradiation in stage III NSCLC. SLCG 10/02.
Provencio-Pulla, Mariano; (...); Isla, Dolores
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e20521. 2018
First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
Andric, Z. G.; (...); Ciardiello, F.
Meeting Abstract. 2021
First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is...
Juan, O, Yousaf, N, Popat, S
Editorial Material. 10.1016/j.clon.2016.09.007. 2017
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Reck, Martin; (...); John, Tom
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Paz-Ares, L.; (...); Carbone, D. P.
Meeting Abstract. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
Reinmuth, N.; (...); John, T.
Meeting Abstract. 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares, Luis; (...); Reck, Martin
Article. 10.1016/S1470-2045(20)30641-0. 2021
First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
Carbone, D.; (...); Lu, S.
Meeting Abstract. 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; (...); John T
Article. 10.1016/j.esmoop.2021.100273. 2021
Follicular lymphoma: clinical and mollecular characteristics of histologic transformation
Garcia, MM; (...); Pulla, MP
Meeting Abstract. 2017
Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Pros, E; (...); Sanchez-Cespedes, M
Meeting Abstract. 10.1016/j.jtho.2019.08.878. 2019
Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population
Fernandez-Mateos, J; (...); Cruz-Hernandez, JJ
Article. 10.3390/cancers11040493. 2019
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; (...); Sanchez-Cespedes M
Article. 10.1016/j.annonc.2019.09.001. 2020
Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience.
Girones, R; (...); Juan-Vidal, O
Article. 10.1111/ecc.12950. 2018
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
Gisbert JP; (...); McNicholl AG
Article. 10.1111/apt.13128. 2015
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM
Article. 10.1016/j.ejca.2020.10.002. 2020
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke
Puig, J; (...); Castellanos, M
Article. 10.1371/journal.pone.0188238. 2017
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.2147/OTT.S214319. 2019
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients
Escoin-Perez C, Blasco S, Juan-Vidal O
Review. 10.1016/j.lungcan.2020.03.026. 2020
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Guckenberger, M; (...); Stahel, RA
Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
Provencio, M; (...); GOTEL Spanish Lymphoma Oncology Gr
Article. 10.1371/journal.pone.0177204. 2017
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Zugazagoitia, J; (...); Manzano, A
Letter. 10.1183/13993003.02431-2017. 2018
Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection.
García-Ortega A; (...); Martínez-García MÁ
Article. 10.1016/j.jinf.2021.01.003. 2021
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
Pardo-Sanchez, JM; (...); Farras, R
Article. 10.3390/cancers13122980. 2021
Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Rodriguez, LPA; (...); Bunn, P
Meeting Abstract. 2019
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial
Juan Ó; (...); Giner V
Article. 10.1016/j.cllc.2014.11.006. 2015
Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital.
Ibáñez-Martínez E; (...); Pemán J
Case Reports. 10.1016/j.riam.2021.06.002. 2021
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
Merino, LD; (...); Dominguez, AR
Meeting Abstract. 2020
LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics
Alcoriza-Balaguer, MI; (...); Lahoz, A
Article. 10.1021/acs.analchem.8b03409. 2019
Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2021
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; (...); de Sevilla AF
Article. 10.1007/s00277-020-04056-9. 2020
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
De Castro, J; (...); Isla, D
Article. 10.1007/s12094-016-1527-8. 2017
Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin Et Radiotherapy in Locally Advanced NSCLC
Juan, O; (...); Hernandez, AS
Meeting Abstract. 10.1016/j.jtho.2016.11.1159. 2017
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07
Isla, D; (...); Garrido, P
Article. 10.21873/anticanres.11273. 2016
Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).
Calvo, V; (...); Provencio, M
Meeting Abstract. 2021
Lung cancer symptoms at diagnosis: results of a nationwide registry study.
Ruano-Raviña A; (...); Cerezo S
Article. 10.1136/esmoopen-2020-001021. 2020
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P; (...); Felip, E
Article. 10.1002/cam4.4135. 2021
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Lopez, PG; (...); Calvo, JP
Meeting Abstract. 2018
LungBEAM: A Prospective Multicenter Trial to Monitor EGFR Mutations Using BEAMing Technology in Stage IV NSCLC Patients
Garrido, P; (...); Palacios, J
Meeting Abstract. 10.1016/j.jtho.2017.09.584. 2017
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Remon, J; (...); Reguart, N
Article. 10.1016/j.lungcan.2020.06.034. 2020
Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors
Pulido, I; (...); Carretero, J
Meeting Abstract. 10.1158/1538-7445.AM2018-LB-099. 2018
Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Angelats, L; (...); Carcereny, E
Meeting Abstract. 10.1016/j.jtho.2019.08.808. 2019
MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.
Ciardiello, Fortunato; (...); Galffy, Gabriella
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.TPS9123. 2019
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
Franco, F; (...); Provencio, M
Article. 10.3390/curroncol28020118. 2021
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S; (...); Nadal, E
Review. 10.1016/j.critrevonc.2019.03.017. 2019
Mutational profile of primary breast diffuse large B-cell lymphoma
Franco, F; (...); Sanchez-Beato, M
Article. 10.18632/oncotarget.21986. 2017
nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D; (...); Ong TJ
Article. 10.3389/fonc.2020.569715. 2021
Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
Spigel, D; (...); Thomas, M
Meeting Abstract. 10.1016/j.jtho.2019.08.604. 2019
nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
Spigel, DR; (...); Thomas, M
Meeting Abstract. 2018
nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm
Gridelli, C; (...); Jotte, R
Meeting Abstract. 2017
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.
Thomas, M; (...); Gridelli, C
Article. 10.2147/LCTT.S138570. 2017
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; (...); ABOUND.sqm Investigators
Article. 10.1016/j.cllc.2020.09.007. 2021
Neumorraquis y neumomediastino espontaneo, rara complicacion asmatica.
Fernandez Garcia C; (...); Gomez J
Article. 10.1016/j.anpedi.2014.11.008. 2015
NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
Rodriguez-Abreu, D; (...); Majem, M
Meeting Abstract. 10.1016/j.jtho.2018.08.1467. 2018
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2021
Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the radical treatment for the primary tumor and the metastases
Marin, S.; (...); Llombar Cussac, A.
Meeting Abstract. 10.1016/S1556-0864(16)30254-4. 2016
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.
Mesía R; (...); Pujol E
Article. 10.1007/s11864-019-0686-6. 2019
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D; (...); Provencio M
Article. 10.1016/j.lungcan.2018.11.041. 2019
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G; (...); Mitsudomi, T
Article. 10.1016/S1470-2045(16)30508-3. 2016
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; (...); Calvo V
Article. 10.1186/s12885-021-07922-5. 2021
OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
Terrasa, J; (...); Provencio, M
Meeting Abstract. 2021
Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.
Perez, Concepcion; (...); Mira, Jose J.
Article. 10.3390/jpm11020102. 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; (...); Besse B
Article. 10.1016/j.cllc.2021.07.008. 2021
Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021
Perspectives in oligometastatic brain lesions in non-small cell lung cancer (NSCLC)
Salvador Coloma, C.; (...); Juan, O.
Meeting Abstract. 10.1016/S1556-0864(16)30255-6. 2016
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.2501. 2019
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
Morillo, ED; (...); Spanish Head Neck Canc Cooperative
Article. 10.1016/j.oraloncology.2016.09.009. 2016
Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG)
Remon, J.; (...); Provencio, M.
Article. 10.1016/S0959-8049(16)31715-4. 2015
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients
Martin, P; (...); Garde-Noguera, J
Meeting Abstract. 10.1016/j.jtho.2016.11.1880. 2017
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde-Noguera, J; (...); Juan-Vidal, O
Article. 10.1007/s12094-017-1829-5. 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)
Garde-Noguera, J; (...); Juan-Vidal, O
Correction. 10.1007/s12094-018-1916-2. 2018
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
Bondarenko, I; (...); Reinmuth, N
Meeting Abstract. 2018
Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Felip, E.; (...); Ganti, A.
Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021
Presence and evolution of multiple pulmonary nodules with halo sign detected by computerized tomography in advanced heart failure
Vilella, RRL; (...); Bonet, LA
Meeting Abstract. 2018
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study
Esteban, E.; (...); Provencio, M.
Article. 10.1016/j.canep.2015.02.003. 2015
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Franco Pérez F; (...); Provencio M
Article. 10.1016/j.clml.2016.09.004. 2017
Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Gutierrez, L; (...); Provencio, M
Article. 10.1186/s12885-021-08713-8. 2021
Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.
Bruixola, G; (...); Cervantes, A
Article. 10.1136/esmoopen-2018-000425. 2018
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group
Provencio, M; (...); Spanish Lymphoma Oncology Grp
Article. 10.1002/cncr.30795. 2017
PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
Spigel, DR; (...); Reck, M
Meeting Abstract. 2021
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa, Lucia; (...); Sanchez-Beato, Margarita
Article. 10.1038/s41598-020-80376-0. 2021
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP
Article. 10.3389/fonc.2021.695038. 2021
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+
Talbot, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.649. 2018
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Aix, SP; (...); Morgensztern, D
Article. 10.2217/fon-2019-0796. 2020
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Peters, S; (...); EMPHASIS-lung Collaborative Group
Article. 10.1016/j.jtho.2016.12.017. 2017
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results
Reck, M; (...); Nakagawa, K
Article. 10.1016/j.cllc.2017.11.003. 2018
Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study
Carpeno, JD; (...); Rojo, F
Meeting Abstract. 2019
Recommendations of GeSIDA/PETHEMA on the Diagnosis and Treatment of Lymphomas in Patients Infected by the Human Immunodeficiency Virus
Miralles, P; (...); Santasusana, JMR
Editorial Material. 10.1016/j.medcli.2017.11.037. 2018
RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares, Luis; (...); Bunn, Paul A.
Article. 10.1002/cncr.34123. 2022
RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
Ponce, S; (...); Bunn, PA
Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020
RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2020
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Paz-Ares, Luis G.; (...); Bunn, Paul
Meeting Abstract. 2020
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer-Preliminary findings from part 1 dose-defining phase.
Paz-Ares, Luis G.; (...); Bunn, Paul A.
Meeting Abstract. 2019
RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
Conde, E.; (...); Lopez-Rios, F.
Meeting Abstract. 2021
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
Bruixola, G; (...); Borgonon, MP
Meeting Abstract. 2018
Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Juan, O; (...); Girones, R
Meeting Abstract. 10.1016/j.jtho.2016.11.1255. 2017
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Spigel DR; (...); Reck M
Article. 10.1016/j.annonc.2021.01.071. 2021
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma
Provencio Pulla M; (...); Rueda Domínguez A
Article. 10.1007/s12094-015-1437-1. 2015
SEOM clinical guidelines for the treatment of Hodgkin's lymphoma
Rueda Domínguez A; (...); Provencio Pulla M
Article. 10.1007/s12094-015-1429-1. 2015
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
Majem M; (...); Provencio M
Article. 10.1007/s12094-018-1978-1. 2019
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Martínez-Trufero J; (...); Mesía Nin R
Article. 10.1007/s12094-021-02567-z. 2021
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Article. 10.21037/tlcr-21-504. 2022
Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Castro, RL; (...); Provencio, M
Meeting Abstract. 2019
Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma
Franco, F; (...); Pulla, MP
Meeting Abstract. 2017
Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
Mielgo-Rubio X; (...); Couñago F
Editorial Material. 10.5306/wjco.v11.i12.983. 2020
Survival in young adults diagnosed with follicular lymphoma
Calvo, V; (...); Rueda, A
Letter. 10.1093/annonc/mdv627. 2016
Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Blanco, R; (...); Vidal, OJJ
Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Edelman, M; (...); Deng, CQ
Meeting Abstract. 2020
Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients
Wilhelmina Bracht, Jillian; (...); Rosell, Rafael
Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Mendez, M; (...); Provencio, M
Article. 10.1002/hon.2601. 2019
Transient pulmonary nodules with halo sign in patients with advanced heart failure: a report of two cases.
López-Vilella R; (...); Bonet LA
Article. 10.1016/j.clinimag.2019.11.008. 2020
Translating cancer epigenomics into the clinic: focus on lung cancer
Mari-Alexandre, J; (...); Sandoval, J
Review. 10.1016/j.trsl.2017.05.008. 2017
Tratamiento con afatinib en primera linea EGFR M+. Resultados segun subtipo de mutacion.
Article. 10.1016/S0025-7753(16)30258-5. 2016
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Juan, O, Popat, S
Review. 10.1177/1758834016687262. 2017
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
Garon, EB; (...); Nakagawa, K
Article. 10.1016/j.cllc.2016.05.023. 2017
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.
Isla D; (...); Juan-Vidal O
Article. 10.1007/s12094-020-02518-0. 2021
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon, J; (...); Sanchez-Beato, M
Article. 10.1371/journal.pone.0212813. 2019
Use of Geriatric Assessment (GA) in Clinical Practice for Stage IV Non-Small Cell Lung Cancer (NSCLC). The GIDO Experience
Girones, R; (...); Juan, O
Meeting Abstract. 2017